Merus N.V.: The Bispecific Antibody Pioneer

I. Introduction & Episode Roadmap

On a Sunday evening at the end of September 2025, two boardrooms, one Dutch and one Danish, a few hundred miles apart, said yes to the same piece of paper. Monday morning brought the announcement. Genmab, the Copenhagen antibody company that had spent a quarter of a century turning laboratory ideas into royalty streams, would pay $97 a share in cash for Merus N.V., a cancer-drug developer headquartered in Utrecht, the old university city in the middle of the Netherlands. The total came to about $8.0 billion.¹ The price was roughly 41% above where Merus shares had closed the previous Friday, and both boards had approved it unanimously.¹

For a company that had never earned an annual profit, that is a remarkable number. Over its first twelve years of reported accounts Merus lost roughly $830 million and burned more cash than that, about $876 million of free cash flow, while never paying a cent in dividends.² In its final full year as an independent company it booked about $36 million of revenue and spent more than six times that on research.² On any conventional yardstick, Merus was a cost centre. Yet a sophisticated buyer, one of the few companies in the world that truly understands how antibodies are invented, built and sold, decided it was worth eight billion dollars.

This story is about why. It is a story about a mouse engineered to make a single kind of light chain, about a twenty-year bet that two-armed antibodies could be built as easily as ordinary ones, and about a company that spent most of its life renting out its invention to bigger partners before deciding, late and expensively, to keep one molecule for itself. That molecule, petosemtamab, is the reason Genmab paid what it paid. One week before this story was written, on October 28, 2026, Genmab announced that petosemtamab combined with Merck's Keytruda had cut the risk of death by half against Keytruda alone in first-line head and neck cancer, at the first interim look of a Phase 3 trial.³

So the hook is a question worth sitting with. How did a small Dutch biotech founded by academic scientists in 2003 win the first FDA approval of a therapy for NRG1-fusion cancers, design a drug that may change the standard of care in head and neck cancer, and get bought for $8 billion, all without ever proving it could stand on its own two feet financially?

The answer runs through four themes. The first is scientific invention as a competitive moat, and how fragile that moat can be. The second is the tension between being a platform company that licenses its technology and a product company that owns its drugs. The third is the partnership model: how Merus funded itself with other people's money, and what that cost it in control. The fourth is the twenty-year overnight success, the long stretch of dilution, losses and patience that sat behind a single takeover headline.

The story starts with a biology problem that defeated much of the industry for decades. To understand Merus, one first has to understand why making an antibody with two different hands was so hard.

Subscribe on LinkedIn

↑ Back to Top

II. The Science Foundation: Understanding Bispecific Antibodies

Picture an ordinary antibody as a capital letter Y. The two short arms at the top are identical hands, each shaped to grab one specific target, a protein on the surface of a cancer cell, say. The stem at the bottom is the handle the immune system recognises. When a drug company makes a classic monoclonal antibody, such as Herceptin or Keytruda, both hands grab the same thing. Medicine has built much of modern oncology on that simple design.

A bispecific antibody gives the Y two different hands. One arm might grab a growth receptor on a tumour while the other grabs a second receptor on the same cell. Or one arm might grab the tumour while the other grabs a killer T cell from the immune system and drags it over to do its work. The appeal is obvious: two targets, one molecule. There is a subtler advantage too. If one arm alone has no functional effect, then a healthy cell that carries only one of the two targets is largely spared, because the drug only does its real work where both targets are present together. That is a way to aim more precisely at cancer and less at everything else.

The problem was making the things. An antibody is built from four protein chains: two long heavy chains, which form the stem and half of each arm, and two short light chains, which complete each arm. When a cell is asked to produce an antibody with two different arms, it has to make two different heavy chains and two different light chains, and then those chains assemble at random. Heavy chain A pairs with heavy chain B only some of the time; it also pairs with itself. Light chain A drifts onto heavy chain B. Chemists who worked through the combinations found that a cell left to its own devices produces a mess of up to ten different molecules, only one of which is the drug that was wanted. Separating that one from its nine misshapen siblings at industrial scale was expensive and often impractical.

The industry's answer, for years, was to abandon the natural shape. Companies chopped antibodies into fragments and stitched the pieces together, producing small, clever molecules that could bind two targets but lacked the stem. Without the stem, they lost the features that make ordinary antibodies such good medicines: a long life in the bloodstream, so a patient might need a dose every two or three weeks instead of a continuous infusion; low risk of the body rejecting the drug as foreign; and the ability to recruit the immune system's own killer cells through the handle.

Merus took the opposite route. Its founding idea was to keep the full-length, natural-looking human IgG antibody, stem and all, and solve the assembly problem inside the cell. The trick had two parts. The first was to make every antibody in its library share one common light chain. If both arms use the same light chain, then the light-chain mispairing problem vanishes, because there is nothing to mismatch. The second was to engineer the base of the two heavy chains with opposite electrical charges, so that heavy chain A attracts heavy chain B and repels copies of itself, like the north and south poles of two magnets. Merus combined common light chains in the arms with that charge engineering in the stem to drive cells to make mostly the right molecule.[^4]

The result, which Merus branded Biclonics, could be produced, the company said, at high yields from a single manufacturing cell line using the same standard processes that the industry already used for ordinary antibodies.[^4] That claim mattered more than it sounds. It meant a Merus bispecific could, in principle, be made in any contract manufacturing plant that made conventional antibodies, rather than requiring an exotic, bespoke process.

The second consequence was even more important for the business. Because every antibody arm in the Merus library used the same light chain, any arm could be snapped together with any other arm. A library of a few hundred arms against dozens of targets could generate thousands of distinct bispecific combinations, all in the same format, all ready to test side by side. Merus could screen not for whether a molecule bound its targets, which is easy to predict, but for what it actually did to a cancer cell, which is not. That functional screening, run in bulk, became the company's way of finding surprises: combinations of targets and orientations that nobody would have designed on a whiteboard.

That is the scientific promise. But a common light chain is only useful if there is a way to make thousands of good antibody arms that all work with it. For that, Merus needed a mouse.

↑ Back to Top

III. Founding & Early Years (2003–2015)

The founding scene of Merus is not a garage. It is a vivarium. Ton Logtenberg, a Dutch immunologist who would run the company for its first sixteen years, came out of the Utrecht academic and biotech world that had already produced an earlier generation of Dutch antibody ventures.⁴ Merus was incorporated in 2003, and its early bet was on a genetically engineered mouse that the company would name MeMo.⁵

The idea of a transgenic mouse for drug discovery was not new. Companies such as Regeneron and Medarex had already built mice whose immune systems produce human antibodies rather than mouse ones, so that a drug discovered by immunising the animal could go straight into people. Merus' twist was to build a mouse that made human antibodies with a huge repertoire of heavy chains but only one, fixed, human light chain. Many immunologists doubted such an animal would mount a normal immune response at all. The light chain contributes to how an antibody recognises its target; take away its diversity, and the immune system might simply not work.

Merus spent years proving the doubters wrong. In a 2016 announcement the company described the full validation of MeMo: a single human light chain, it said, drove the generation of a normal population of antibody-making B cells and supported a robust immune response, with antibodies that compared well with platforms using diverse heavy and light chains.[^4] Those are company claims, not independent trial data, but they were backed by the thing that mattered commercially: the mouse produced arms that could be combined into bispecifics in bulk.

Building a mouse is slow and building patents around it is slower. Merus filed for protection on the mouse and on the methods of making bispecifics in single cells, and the company later said that European and Japanese rulings protected the mice and their use through 2029.[^4] Then came the fight that every platform company eventually faces. In 2014, Regeneron, whose own humanised-mouse technology underpinned a multibillion-dollar franchise, sued Merus for patent infringement in New York. A small Dutch company could easily have been crushed by the legal bill alone. Instead the case turned. A federal district court found Regeneron's patent unenforceable because of inequitable conduct during its prosecution, and on July 27, 2017, the Federal Circuit affirmed that ruling two to one, drawing an adverse inference about intent from what the court called widespread litigation misconduct.⁶ For Merus it was more than a legal win. It removed the largest single threat to its freedom to use its own mouse, at the moment the company was trying to persuade partners to pay for that mouse's output.

Through these years Merus lived on venture capital and modest deals. Its first notable licence was with the Japanese drugmaker 小野薬品工業 (Ono Pharmaceutical). In April 2014 the two companies signed a research and licence agreement to develop bispecifics, which in Ono's hands turned towards autoimmune disease; in March 2018 Ono exercised an option for a new agreement, and the candidate that emerged, ONO-4685, earned Merus a milestone when Ono filed to start human trials in Japan in 2019.⁷ It was a small cheque, but it was the first sign of a pattern: Merus' science would be validated, and partly paid for, by companies far larger than itself.

The financial reality of those years was stark. Revenue was effectively nil. Operating losses grew from about $10 million in 2013 to about $23 million in 2015, and at the end of 2014 shareholders' equity had gone negative, which is what happens when a company spends more than its investors have put in.⁵ The company was a scientific success story trapped inside a financial survival story. To grow out of it, Merus needed a deeper pool of capital than Dutch venture funds could provide.

By 2015 it had two lead clinical candidates moving forward. One, which would become zenocutuzumab, targeted HER2 and HER3 and was designed to block a growth signal at its source. The other, MCLA-117, targeted CD3 on T cells and CLEC12A on leukaemia cells. Pursuing those in human trials meant tens of millions of dollars a year. The obvious place to find that money, for a European biotech in 2016, was not in Amsterdam. It was on Nasdaq.

↑ Back to Top

IV. The IPO & Strategic Pivot (2016)

May 2016 was not a kind month for biotech IPOs. The sector had peaked the previous summer, and investors who had chased every gene-editing and immuno-oncology story were now nursing losses and demanding discounts. Merus walked into that market with a ticker, MRUS, and a plan to sell about 4.3 million shares at $14 to $16 each.⁸

The market said no to that price. On May 18, 2016, Merus priced its offering at $10 a share, well below the bottom of the range, and sold more shares to compensate: 5.5 million, raising $55 million.⁸⁵ On the first day of trading the shares barely moved. Bankers like to describe such a deal as "getting it done." What it really meant was that the founders and early backers accepted about a third less per share than they had hoped, and that the company would have to earn its credibility after listing rather than before. For investors, the lesson of that discounted debut is worth keeping in mind: public markets at the time valued the Biclonics platform at well under $200 million. The world had not yet decided it was special.

Seven months later, the world changed its mind. On December 20, 2016, Merus signed a collaboration and licence agreement with Incyte, the Delaware oncology company built on the success of Jakafi, and announced it the next day.[^10] The terms were extraordinary for a company of Merus' size. Incyte agreed to pay $120 million upfront and to buy 3.2 million new Merus shares at $25 each, an $80 million investment.⁹ That $25 price was two and a half times the IPO price of seven months earlier. In a single transaction Merus received roughly four times what its public offering had raised.

What did Incyte get? Rights to up to eleven bispecific antibody research programmes using Merus' platform.[^10] For eight of those, Incyte would fund development, and Merus became eligible for milestones of up to $350 million per programme plus royalties; for the remaining three, Merus kept rights to co-fund development and share in commercialisation.⁹ Multiply eight programmes by $350 million and the press-release arithmetic reaches $2.8 billion, which is where the headline "up to $2.8 billion" valuations of the deal came from. That number deserves a raised eyebrow. Biobucks are hypothetical. They are the sum of every milestone that would be paid if every programme succeeded, which almost never happens.

The equity stake also mattered. Incyte's 3.2 million shares represented 19.9% of the shares outstanding before the deal, an amount sized to stay just under the 20% level at which many governance thresholds begin to bite.⁹ Merus had acquired a deep-pocketed anchor shareholder. It had also acquired a partner who held options over a large share of its future discovery work.

This was the strategic pivot. Before Incyte, Merus was a platform hoping someone would notice it. After Incyte, it was a platform with a validating customer, a war chest and a choice. It could keep renting out its discovery engine, collecting upfront payments and hoping for royalties. Or it could use that money to push its own molecules through the clinic and capture the full value of a drug. For most of the next eight years it tried to do both, and the tension between those two models runs through the rest of this story.

The Incyte deal also revealed something about how the market values platforms. Public investors had priced Merus at a discount in May. A sophisticated industry buyer, with full access to the data, paid a large premium in December. The gap between those two judgments, between what outsiders could see and what insiders were willing to pay, would reappear at almost every turning point, including the very last one.

↑ Back to Top

V. The Partnership-Driven Model & Key Inflection Points (2016–2021)

There is a particular kind of meeting that happens at the J.P. Morgan Healthcare Conference in San Francisco every January. In hotel suites near Union Square, small companies with clever platforms pitch large companies with full wallets, and occasionally the two leave with a term sheet. For Merus, the years after the IPO were a long sequence of such meetings, and the pattern of who said yes tells a great deal about what the platform was really worth.

The Incyte collaboration was the first and largest inflection point, and it set the economic template. Merus would do early research, the partner would fund development, and Merus would recognise revenue over time as it performed its research obligations. That accounting detail explains why Merus' revenue rose from roughly $2 million in 2016 to about $33 million in 2018: the company was not selling more of anything, it was gradually booking a large upfront payment it had already received.² Over the following years the Incyte relationship evolved in ways that show the risks of depending on a partner's priorities. In January 2022 Incyte elected to opt out of its ex-U.S. development of MCLA-145, a bispecific that had emerged from the collaboration, handing full global rights back to Merus.² Incyte's ownership stake also drifted down from 8.2% in 2021 to below the 5% reporting threshold.¹⁰¹¹ A partner that once anchored the company was gradually stepping back.

The Ono relationship was the second strand, quieter and steadier. It produced a clinical candidate in an area, immunology, that Merus itself had no intention of pursuing. That was the platform model at its cleanest: Merus earned option fees and milestones for work that sat entirely outside its own strategy.⁷

The third inflection point came on January 18, 2021, when Merus signed a research collaboration with Eli Lilly, through its Loxo Oncology unit, announced the following day.¹² Lilly wanted up to three T-cell engaging bispecifics, molecules where one arm grabs CD3 on a T cell. Merus would lead discovery and early research at Lilly's expense; Lilly would take over research, development and commercialisation. The economics were $40 million in upfront cash, a $20 million equity investment, and up to $540 million per product in development and commercial milestones, so roughly $1.6 billion for all three, plus tiered royalties.¹²

Put the Incyte and Lilly deals side by side and a picture forms. Between them, they brought Merus about $260 million in upfront payments and share purchases at a time when the company's annual operating losses were running between $35 million and $80 million.²⁹¹² That is the non-dilutive funding argument in its strongest form: partners paid for a meaningful slice of Merus' existence. Later, in March 2024, Gilead joined the list, paying $56 million upfront and buying $25 million of shares to use Merus' three-armed Triclonics format for trispecific T-cell engagers, with up to $1.5 billion of potential payments and an option for Merus to share profits and losses on one programme.¹³

Now test that argument against the record. The partnership model's promise was that platform deals would fund the company while it built its own drugs, keeping dilution modest. What actually happened is that partnership money covered the early years and then became a rounding error against Merus' own ambitions. Over its first twelve years of accounts, Merus raised far more from equity investors than from partners. Its May 2024 public offering alone brought in about $435 million net, and it raised about $226 million from share issuance in 2023 and another $326 million in the first nine months of 2025.²¹⁴ Shares outstanding rose from 68.8 million at the end of 2024 to 75.8 million by September 2025, roughly 10% more in nine months.¹⁴ The partnerships were real, and they validated the science. But they did not spare shareholders from dilution once Merus decided to run Phase 3 trials on its own.

There is a second test, harder still. How often did the partnerships convert into actual royalty-bearing products? By the time Merus was sold, none of the partnered programmes had produced an approved drug, and no development or commercialisation milestones were achieved in 2025 through September.¹⁴ In fiscal 2024, three partners, Incyte, Lilly and Gilead, accounted for almost all of Merus' roughly $36 million of revenue, and about $28 million of it came from recognising upfront payments rather than from milestones or royalties.² The platform was validated by contracts, not yet by commercial outcomes. That does not make the deals failures; drug discovery collaborations take a decade to bear fruit. It narrows the claim. The Biclonics platform reliably attracted partners and their upfront cash. It had not yet proved it could turn partner programmes into a recurring royalty stream.

By the end of this period the company also had a new kind of leader. In December 2019, after sixteen years at the helm, founder Ton Logtenberg stepped down as chief executive, staying on as a senior adviser, and the board named Sven "Bill" Lundberg, a physician who had joined Merus' board only that June, to succeed him.⁴ The choice said a lot about where the board wanted to go. Logtenberg was the inventor-founder, the man of the mouse. Lundberg was a drug developer. He had been chief scientific officer of CRISPR Therapeutics, where he built its U.S. research and development operation, and before that head of translational medicine at Alexion, the rare-disease company, where his job was to move molecules from the lab into patients.⁴ He arrived with a reputation for clinical focus rather than platform evangelism.

The handover is worth pausing on because it marks the hinge of the whole story. Under the founder, Merus' identity was its technology, and its strategy was to multiply the number of programmes and partners. Under Lundberg, the company's identity narrowed towards a small number of its own clinical assets. Within a few years, the pipeline story Merus told investors was dominated by two names, zenocutuzumab and petosemtamab, rather than by the number of Biclonics programmes in partners' hands. Gregory Perry, the chief financial officer since 2016, stayed on to run the capital-raising machine that the new strategy would require.¹⁵ The founder had built the engine. The new chief executive decided which car to put it in.

That record, and its limits, explains the decision that defined Merus' final act. If partners would pay tens of millions for options on its science, what would the company be worth if it kept the best molecule for itself? To answer that, Merus first had to keep improving the engine.

↑ Back to Top

VI. Platform Evolution: From Biclonics to Multiclonics

Return for a moment to the image of the Y. Biclonics gave it two different hands. The obvious next question for an inventor is: why stop at two?

Merus' answer was Triclonics, a format for trispecific antibodies that can grab three targets at once, part of a broader family of formats the company called Multiclonics.¹³ The logic extends naturally from the common light chain: adding a third binding domain does not reintroduce the mispairing problem. In principle, an antibody could grab two different markers on a tumour and a T cell at the same time, so that it only activates the immune system when both tumour markers are present. That is the design Gilead paid for in 2024: dual tumour-targeting trispecific T-cell engagers.¹³

The engine behind every one of these formats was the same high-throughput functional screen. Merus' practice, as it described it, was to generate up to thousands of candidates from its libraries and test them in cell-based assays, then select the few that showed unusual biology.² That functional screen was the company's real intellectual edge, more than any single patent. Petosemtamab, the molecule that made the company, emerged from exactly that kind of screening.

Then came the frontier of antibody-drug conjugates, or ADCs. An ADC is an antibody used as a delivery truck, carrying a toxic chemical payload directly to a cancer cell. ADCs became a major deal category in oncology in the early 2020s, and a bispecific ADC, an antibody that only docks and releases its payload where two targets are present, was a natural extension of Merus' thinking. In January 2025 Merus signed a research collaboration and licence agreement with Biohaven to co-develop three bispecific ADCs, pairing Merus' antibodies with Biohaven's conjugation and payload technologies.¹⁴ The deal produced revenue, but it also produced an early awkward detail: by September 30, 2025, Merus had billed about $14.1 million under the Biohaven arrangement and recorded only $9,000 of receipts against it.¹⁴ The balance was not reported as overdue, and Merus did not provide an ageing table, so it remained a watch item rather than evidence of a problem. It was still a reminder that a partner is a counterparty, with its own balance sheet and its own priorities.

How strong was this engine really? The bullish case is that Merus kept extending its technology into new formats faster than most rivals, and partners kept validating each new format with money. The bearish case is that the most valuable Merus molecules so far have been bispecifics, not trispecifics or ADCs, and none of the newer formats has produced clinical data that proves superiority. Competitors were not standing still either. The broader industry, including Genmab itself with its DuoBody technology and Xencor with its own Fc engineering, had developed workable bispecific formats too, and Merus' patent suit against Xencor was dismissed with leave to amend in September 2025, while Xencor filed two patent-review challenges against Merus' patents.¹⁴ A pending appeal involving a Kymab patent also hung over the estate, though Merus said it expected no significant impact.¹⁴

The verdict on the platform, then, is that it was genuinely productive and genuinely differentiated in its screening approach, but that its legal walls were contested and its newer formats were still promises. What would make or break the company was not the platform in the abstract. It was whether any single molecule from it could become a medicine. The first answer came from a rare kind of lung cancer.

↑ Back to Top

VII. The BIZENGRI Breakthrough: First FDA Approval (2024)

Imagine a patient in her forties who has never smoked and has been diagnosed with advanced lung cancer. Her oncologist runs a genetic panel on the tumour, looking for the mutations that now have targeted pills: EGFR, ALK, ROS1. Nothing. But deep in the report there is a rarer finding, a fusion in a gene called NRG1, in which a piece of the NRG1 gene has broken off and welded itself onto another gene. Before December 2024, that finding led nowhere. There was no approved therapy aimed at it.

NRG1 fusions drive cancer in a specific way. The fused gene makes a signalling protein, neuregulin, that latches onto a receptor called HER3 on the cancer cell. HER3 then pairs up with its cousin HER2, and together they send a relentless "grow" signal into the cell. Merus' zenocutuzumab was designed to break that handshake. One arm docks onto HER2, positioning the antibody so that the other arm can block HER3 from receiving the neuregulin signal. The company called this its "dock and block" mechanism.

On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco, sold as Bizengri, for adults with advanced non-small cell lung cancer or pancreatic adenocarcinoma harbouring an NRG1 gene fusion whose disease had progressed after prior systemic therapy. It was the first FDA approval of any systemic therapy for patients with those cancers carrying an NRG1 fusion.¹⁶ The application had received priority review, breakthrough therapy designation and orphan drug designation.¹⁶

The evidence was respectable but not spectacular. In the eNRGy trial, about one in three lung cancer patients, 33% of 64, saw their tumours shrink meaningfully, and 40% of the 30 pancreatic cancer patients did.¹⁶ The label carried a boxed warning for embryo-foetal toxicity, and because the approval was accelerated, based on response rates rather than survival, Merus was required to run confirmatory trials to verify clinical benefit.¹⁶ To put that response rate in context: in a population that previously had no targeted option, shrinking tumours in a third of patients is a genuine advance. It is not the 70% to 80% response rates seen with the best targeted pills in more common lung-cancer mutations.

The commercial decision around Bizengri said even more than the approval. Two days before the FDA acted, Merus announced that it had exclusively licensed U.S. commercialisation rights to Partner Therapeutics, a private oncology and haematology company, in exchange for an undisclosed upfront payment, milestones and royalties reported in the high single digits to low double digits on annual net sales.¹⁷ In other words, Merus won its first approval and immediately handed the selling to someone else.

Why would a company spend a decade developing a drug and then license away most of its U.S. economics on the eve of approval? The honest answer is arithmetic. NRG1 fusions are rare, found in a small fraction of lung and pancreatic tumours, and finding those patients requires sophisticated RNA-based testing that is not yet universal. Building a sales force to hunt for them would have cost Merus tens of millions of dollars a year for a modest revenue stream, and would have distracted management from the much larger opportunity in petosemtamab. Licensing Bizengri crystallised its value and kept Merus focused. It also meant that the company's first approved product would never become a meaningful source of revenue in its own right. Merus does not disclose Bizengri royalty income separately, and its 2025 revenue remained dominated by collaboration accounting rather than product economics.¹⁴

There was also a competitive story. For a while Merus had a rival in the NRG1 niche: Elevation Oncology's seribantumab, which had reported a similar one-in-three response rate. In January 2023 Elevation paused further investment in seribantumab and said it would continue only with a partner, and its Phase 2 trial was later terminated as a business decision.¹⁸ The competitor that might have shared the niche had walked away, which says something about how small the commercial prize looked to everyone involved.

Here is the investor's takeaway, and it is a useful corrective to a common narrative. Bizengri is often cited as proof that Merus' platform could produce approved drugs, and that is true: it was a first-of-its-kind approval, earned through a novel mechanism. But approval is not commercialisation. Bizengri validated the science and the regulatory path; it did not validate the business model. That job fell to a molecule with a much larger patient population and a much stranger origin story.

↑ Back to Top

VIII. Petosemtamab: The Crown Jewel & Path to Acquisition

Head and neck cancer is a brutal disease to live with and a brutal one to treat. Tumours grow in the mouth, throat and larynx, places that govern eating, speaking and breathing. When the cancer returns after surgery and radiation, or spreads, the standard first treatment for many patients since 2019 has been Keytruda, Merck's checkpoint inhibitor, either alone or with chemotherapy. Even for patients whose tumours express PD-L1, Keytruda alone shrinks tumours in only a minority. Most eventually progress. And once they fail both immunotherapy and platinum chemotherapy, the options thin out to older drugs with modest benefit.

Into that landscape came petosemtamab, known in its laboratory days as MCLA-158. It is a full-length bispecific that grabs two targets on cancer cells: EGFR, a growth receptor that has been a cancer target for decades, and LGR5, a marker found on cells thought to behave like cancer stem cells, the seeds from which tumours regrow. Merus designed the molecule to work three ways at once. It blocks EGFR's growth signal. It uses LGR5 binding to pull EGFR into the cell and degrade it. And because its stem has been engineered with less of a sugar called fucose, it is unusually good at calling in the immune system's natural killer cells and macrophages to destroy the cancer cell outright.² This is exactly the kind of molecule that Merus' functional screening was built to find: the EGFR-LGR5 pairing was not an obvious design choice, but it showed striking activity in the lab.

The clinical data built over three years, each update raising the stakes. In patients whose disease had already progressed after immunotherapy and chemotherapy, petosemtamab alone shrank tumours in about 36% of 75 evaluable patients in an update presented at the end of 2024.[^21] In the first-line setting, combined with Keytruda, the early numbers were startling: a 67% response rate among 24 evaluable patients in mid-2024, then, with a February 2025 data cut, 63% among 43 evaluable patients and 79% of patients alive at twelve months.¹⁹[^21] Infusion-related reactions occurred in 38% of patients, mostly mild, though 7% were severe.¹⁹ The FDA granted breakthrough therapy designations both for the first-line combination in PD-L1-positive disease and for later-line monotherapy.¹

Management was not shy about the meaning. Merus said that by essentially every metric it believed these interim data were significantly better than Keytruda monotherapy, the control arm of its own Phase 3 trial.¹⁹ That is precisely the kind of claim a neutral observer should handle carefully. Single-arm Phase 2 results in a few dozen patients often look better than randomised Phase 3 results, because early trials enrol fitter patients at experienced centres and there is no control arm treated at the same time. Many oncology drugs have stumbled exactly at that transition.

There is a structural reason to be wary of such claims from a company in Merus' position. A small biotech that funds itself through share offerings needs its data to look as good as possible at the moment it raises money, and Merus raised equity in 2023, 2024 and 2025, in the same years the petosemtamab data were accumulating.²¹⁴ That does not make the data wrong. It does mean the interim numbers were, by design, the most encouraging available cut, presented by the party with the most to gain from them, and that only a randomised trial against Keytruda could settle the question.

Merus bet the company on that transition anyway. It launched two Phase 3 trials. LiGeR-HN1 randomised first-line PD-L1-positive patients to petosemtamab plus Keytruda or Keytruda alone, with overall survival and response rate as co-primary endpoints; LiGeR-HN2 compared petosemtamab alone against the investigator's choice of therapy in patients who had already failed immunotherapy and platinum.²⁰ Running two global Phase 3 trials is what turned Merus from a moderately loss-making platform company into a heavy cash consumer. Research spending jumped from about $141 million in 2023 to about $225 million in 2024, and then to about $254 million in just the first nine months of 2025.²¹⁴ Headcount grew from 221 employees at the start of 2023 to 260 at the start of 2025, and 190 of those were in research and development.²²¹

This is the moment the platform-versus-product tension was resolved. Merus had licensed Bizengri. It had optioned dozens of programmes to partners. But petosemtamab it kept, wholly owned, and funded with the money it raised from public investors in 2023, 2024 and 2025. That choice explains why the company's value multiplied, and why its losses did too.

Then, a week before this story was written, came the moment that decides whether the bet was right. On October 28, 2026, Genmab announced that LiGeR-HN1 had met both of its co-primary endpoints at the first interim analysis.³ The hazard ratio was 0.50, and the odds of a tumour response were more than three times higher than with Keytruda alone, regardless of whether the cancer was linked to HPV.³ Safety was described as consistent with what was known about each drug, with no new signals.³ The trial's investigators called it the first positive Phase 3 study in that patient population in several years.³

Two cautions belong right next to that triumph. First, the announcement was topline: Genmab disclosed no median survival, no absolute response rates and no patient numbers, and a hazard ratio of 0.50 describes a relative reduction in risk at each moment, not a doubling of how long patients live.³ The full data will be presented at a future medical meeting. Second, LiGeR-HN2, the later-line monotherapy trial, has not yet reported, and colorectal cancer trials remain early.³ What the October result establishes is that the molecule Merus kept for itself worked in the setting that matters most commercially. What it does not establish yet is how large the label, the price and the market share will be.

But Merus' shareholders did not wait for that answer. They sold a year earlier. To understand why, one has to go back to the summer of 2025.

↑ Back to Top

IX. The Genmab Acquisition: The $8 Billion Exit

On May 22, 2025, Merus released the interim first-line data. Within weeks the phones were ringing. Merus' chief operating officer and general counsel, Peter Silverman, had already been authorised earlier that year to seek partners for petosemtamab, and the company had reached out to more than ten potential counterparties.²² Now the conversations turned from partnering to buying.

The bidding history, set out in Merus' own recommendation statement, reads like a negotiation chess game. On August 8, 2025, Genmab proposed $81 a share in cash. The Merus board considered that price not fully informed and kept talking. On September 3, Genmab raised its offer to $87. Merus refused to grant exclusivity at that level and asked for more, including contingent value rights, a common device in biotech deals that pays sellers extra later if a drug hits future milestones. Genmab rejected the contingent payments but on September 18 raised to $95, and on September 19 offered $97 as its best and final price.²² Other interested parties had engaged during the summer but, according to the board, did not raise their offers or propose a comparable deal.²² Exclusivity was signed on September 21, the board approved the transaction on September 28 after Jefferies delivered its fairness opinion, and the agreement was signed on September 29.²²

Three raises from $81 to $97 is a 20% improvement extracted through negotiation, which reflects credit to the Merus board. It also tells an investor something about the buyer. Genmab wanted this asset badly enough to pay up, but not badly enough to give away the upside through contingent payments. Genmab was betting it understood petosemtamab's future better than the sellers did.

Why Genmab, and why then? Genmab had built one of the most successful antibody companies in Europe by inventing molecules and then partnering them, most famously daratumumab, sold by Johnson & Johnson as Darzalex, which paid Genmab royalties. That model made Genmab rich but dependent on royalties that would eventually expire. Genmab's stated rationale was that Merus' pipeline would accelerate its shift from partnered to wholly owned products, expanding and diversifying its revenue and driving growth into the next decade, with a potential petosemtamab launch as early as 2027.¹ There is a neat symmetry in that. Genmab bought Merus to escape exactly the partnership dependence that Merus had spent its life inside. Merus' CEO, Bill Lundberg, said the company was excited to join a leader in antibody therapeutics and believed Genmab had the right vision and experience to advance petosemtamab.¹

Genmab financed the deal with cash on hand and about $5.5 billion of new debt.¹²³ That debt belongs to the parent, not to Merus' history, but it shapes Merus' future, because the cost of developing petosemtamab now competes with interest payments inside a single balance sheet. In the first half of 2026, Genmab reported $174 million of interest expense and $43 million of amortised borrowing fees.[^27] That is roughly the same as a full year of Merus' standalone research budget, paid to lenders in six months.

The mechanics of the close were swift. Genmab's tender offer began on October 21, 2025.²² When it expired on December 11, 94.2% of Merus' shares had been tendered, and Genmab accepted them at $97 effective the next day.[^28] Merus shares stopped trading on Nasdaq on December 30, 2025, and Genmab completed back-end transactions to acquire the remainder, leaving Merus as a wholly owned subsidiary.²⁴²⁵ There is, in other words, no live MRUS share price today. Any quotation that still appears under the old ticker is a stale data artefact; the last observable equity value for Merus is the $97 cash price.

Was $97 the right price? The board pointed to the 41% premium to the last undisturbed close and a 50% premium to the 60-day average, the all-cash certainty, the absence of a higher bid and Genmab's greater resources to run the trials.²² It also listed the negatives honestly: shareholders gave up the upside of the standalone plan, a $240 million termination fee constrained alternatives, and directors and executives had interests that differed from those of ordinary shareholders.²² Merus' management had prepared risk-adjusted long-range projections, shared with the board and Jefferies but not with bidders, that imagined revenue climbing into the billions of dollars a year by the mid-2030s.²² Jefferies opined that the price was fair from a financial point of view; it did not opine on whether Merus might have been worth more standing alone.²²

A skeptical shareholder, the kind of long-short investor who reads proxy statements for sport, would have focused on two things during the sale. The first was who owned Merus. There was no controlling holder. The largest disclosed shareholder at the time of the deal was RTW Investments, a specialist biotech fund, with about 5.5%, while the chief executive, directors and officers together held about 3.9% including exercisable awards.¹¹ Merus was, in other words, a company owned by a dispersed group of institutions, many of them specialist funds that had bought into the 2023 to 2025 offerings and were happy to take a quick, certain return. A dispersed shareholder base makes a tender offer easier to complete, and the 94.2% acceptance that followed confirmed it.

The second was what management stood to gain. Lundberg's reported compensation was about $9.6 million in fiscal 2024, roughly double the prior year, with about $8.4 million of that in option awards, in a year when Merus lost about $215 million.¹⁵ Option-heavy pay is standard in biotech, and option accounting values are notional. But the takeover turned notional into real: the recommendation statement estimated that Lundberg's roughly 2 million options would deliver about $142 million of consideration at $97 a share, on top of shares worth about $19 million.²² Change-of-control severance for the chief executive was set at one and a half times base salary plus target bonus.²² That is a powerful incentive to sell, and incentives to sell do not always align with what is best for the shareholders who must decide whether to hold.

Shareholders noticed. The routine advisory vote on executive pay at the May 2025 annual meeting passed with only about 1.7 million votes against.²⁶ The advisory vote on transaction-related compensation at the December 2025 extraordinary meeting was a different matter: about 29.8 million votes for and about 23.5 million against.²⁷ That is a narrow margin for a resolution that most boards pass with ease. Shareholders approved the deal itself and tendered overwhelmingly, so the dissent was not about the price. It was a pointed message about how much of the takeover's value management was taking home. The vote was advisory, and it changed nothing, but it is the clearest record of where Merus' owners and its managers saw the transaction differently.

Then came the result in October 2026. If the full data and the regulators confirm what the topline suggested, the people who will capture most of petosemtamab's value are Genmab's shareholders, not the Merus shareholders who tendered at $97. That is the classic biotech seller's dilemma, and Merus' shareholders made their choice with eyes open. They took certain cash for an uncertain trial result. A year later, the trial delivered.

↑ Back to Top

X. Business Model & Financial Evolution

To understand the Merus income statement, picture a bucket with a slow tap at the top and a firehose at the bottom. The tap was collaboration revenue. The firehose was research and development. The water level, the company's cash, was kept up not by the tap but by periodic deluges of new equity from investors.

The tap first. Merus earned money from licences, upfront payments, research reimbursements, milestones and, in theory, royalties.² None of it was recurring in the way a software subscription is recurring. When a partner paid an upfront fee, Merus did not book it at once; it recognised it gradually as it performed research obligations. That is why revenue stayed in a narrow band of roughly $25 million to $45 million a year for most of the period after 2017, rising and falling with the progress of partner programmes rather than with any underlying demand.² In fiscal 2024 revenue fell to about $36 million from about $44 million the year before, and about $28 million of the 2024 figure came from recognising upfront payments, with only about $5 million from reimbursements.² The first nine months of 2025 brought a jump to about $47.5 million from about $27 million a year earlier, but that reflected lumpy collaboration accounting, including the new Biohaven deal, not the sale of products.¹⁴

Even the accounting of that tap required judgment. KPMG, Merus' auditor, gave an unmodified opinion on the 2024 accounts but singled out the allocation of the Gilead deal across its distinct obligations as a critical audit matter, the auditor's flag for the area requiring the most difficult judgments.² At the end of 2024, about $51 million of Gilead money sat in deferred revenue, cash received but not yet recognised.² Investors who treated Merus' revenue line as a measure of operating progress were reading an accounting allocation, not a sales figure.

Now the firehose. Research spending continued to climb sharply.²¹⁴ Capital expenditure, by contrast, was tiny: under $2 million in 2024.² Merus owned almost no factories. It rented manufacturing and spent its money on scientists, clinical trial sites and patients. That is the profile of a company being invested in, not harvested. It also meant that nearly every dollar spent was a bet on clinical outcomes, with no physical assets to fall back on if the bets failed.

Two other forces quietly shaped the reported losses, and both are easy to miss. The first was interest income. With hundreds of millions in the bank, Merus earned real money on its cash: in 2024, other income came to about $65 million, made up of about $31 million of net interest and about $34 million of foreign exchange gains.² The second was currency. Merus N.V. kept its books in euros while most of its cash and revenue were in dollars and a large share of its costs were in euros.² When the dollar strengthened in 2024, Merus booked gains; when it weakened in 2025, it booked about $78 million of FX losses in nine months.¹⁴ The company estimated that a 20% move in the dollar against the euro would shift its quarterly net loss by about $19 million.¹⁴ So the audited net loss of about $215 million in 2024 was flattered by currency and interest, while the operating loss was the truer picture of what the business cost to run.²

The water level came from the equity markets. Merus' cash, equivalents and marketable securities stood at about $817 million at the end of September 2025.¹⁴ It got there through equity raises in 2023, 2024 and 2025, while also setting up a $300 million at-the-market programme.²¹⁴ Operating cash outflow over the first nine months of 2025 was about $251 million.¹⁴ At that rate, the September 2025 cash pile represented something like two to three years of runway, comfortable by small-biotech standards but not enough to fund two Phase 3 trials, a regulatory filing and a commercial launch without returning to investors.

One more question belongs here, because it tests whether the reported losses told the truth about cash. Across the twelve years of accounts to 2024, Merus' cumulative net losses of about $830 million were almost exactly matched by about $847 million of cash burned in operations.² That is a reassuring symmetry: there was no hidden gap between accounting losses and the money actually leaving the building. In individual years the two diverged for understandable reasons. In 2024, the net loss of about $215 million exceeded operating cash outflow of about $186 million largely because of about $46 million of non-cash share-based pay, partly offset by the currency gain, which was a profit on paper but not cash.² In 2025 the gap ran the other way, with large non-cash currency losses inflating the reported loss.¹⁴ Receivables were small, about $1.3 million at the end of 2024, all of it unbilled amounts that partners typically settled each quarter.² By September 2025 they had risen to about $19 million, most of it the Biohaven billings that had not yet been collected.¹⁴ Nothing in that pattern suggested aggressive accounting. It suggested a company whose cash was shaped mostly by science and capital raising, with currency as noise in between.

There was also no debt to speak of. Merus' balance sheet at the end of 2024 carried about $10 million of lease obligations and no funded borrowings, and it held its cash in money-market funds, corporate paper, U.S. agency securities and Treasuries rated A-minus or better.²¹⁴ The constraint on Merus was never leverage. It was burn, and the need to keep asking investors for more.

That is the honest verdict on Merus' financial model. It was never designed to be self-funding, and it never pretended to be. Partnerships paid for the platform's early years; public equity paid for the product bet. The cost of that structure was dilution, and the reward, if it came, would be a wholly owned drug. The acquisition converted that reward into cash at a moment of maximum uncertainty, which is either the wisest or the most expensive decision in the company's history, depending on what happens next.

↑ Back to Top

XI. Playbook: Business & Investing Lessons

Every company story eventually becomes a set of lessons. Merus' lessons are unusually sharp because its life was compressed into a few decisive moments: a discounted IPO, a transformative licence, a patent courtroom, a licensed-away approval and a negotiated sale. Each holds a lesson that belongs to this company and few others.

The first lesson comes from Incyte's 2016 investment, which repriced Merus after its discounted IPO. The lesson is that in platform biotech, the most informed price is the one paid in private. Public investors could see Merus' patents and press releases; Incyte could see the data rooms. Founders who are disappointed by a public valuation should remember that a single sophisticated partner can reprice a company overnight, and investors should treat such deals as the market's best evidence of what insiders believe.

The second lesson comes from Bizengri, licensed to another company just before approval. The lesson is that a scientific first is not the same as a business. Bizengri was a genuine medical milestone, and it did almost nothing for Merus' revenue line. The approval proved the platform could produce a drug and the regulator could be persuaded; it did not prove there was a market large enough to justify a sales force. For founders, the takeaway is to judge an asset by the size of the patient population that can be found and treated, not by the novelty of the mechanism.

The third lesson comes from the moment Merus decided to keep petosemtamab wholly owned and fund two Phase 3 trials with public equity. The lesson is that a platform company's value is ultimately set by the one molecule it refuses to license. Merus' decision to keep petosemtamab and absorb the dilution that came with it changed the company's worth. A partnership is a promise of value, not value itself.

The fourth lesson comes from Genmab's final offer: $97 in cash, with no contingent value rights. The lesson is that whoever refuses to share the upside believes in it most. Genmab's willingness to pay cash but not contingent rights told the world that it expected petosemtamab to succeed, and the October 2026 result appears to support that. For investors evaluating biotech takeovers, the structure of the payment, cash versus contingent value, is often more revealing than the headline premium.

The fifth lesson is about the Dutch biotech environment, and it is more modest than the mythology. Utrecht's academic science and the Netherlands' tradition of antibody research supplied the talent and the ideas, and Merus kept its research base there. But the money that built the company came largely from American investors and American and Japanese partners, through a Nasdaq listing. The Dutch advantage was intellectual; the capital advantage lay across the Atlantic. Founders in smaller ecosystems should notice that the two need not be in the same place, but they must eventually meet.

All five lessons converge on a single idea. Merus' competitive position was never a fortress in the way a consumer brand or a network can be. To test whether it had any durable advantage at all, it is worth running the cold arithmetic of competition.

↑ Back to Top

XII. Porter's Five Forces Analysis

The bispecific antibody field in the mid-2020s looked like a gold rush. Roughly a dozen bispecifics had reached the market, hundreds were in clinical trials, and every major pharmaceutical company had either built a bispecific platform or bought one. Merus was one prospector among many, and its position in that rush is best understood force by force.

Consider first the threat of new entrants, which is moderate to high. The barriers Merus erected were real: a validated transgenic mouse, a common light chain approach with patents, and two decades of experience in screening bispecifics functionally. But the field had multiple workable alternatives. Genmab's own DuoBody format, Xencor's Fc engineering, Roche's CrossMab and a raft of Chinese platforms all solved the manufacturing problem in different ways. Its patent dispute with Xencor underscored the limits of those walls.¹⁴ Well-funded newcomers could enter bispecific discovery; what they could not easily replicate was a specific clinical asset with Phase 3 data.

Supplier power was low. Merus relied on contract manufacturers, and the company said Biclonics could be made with standard cell-line processes used for ordinary antibodies.[^4] Merus did not disclose a supplier concentration that would suggest otherwise. This is one place where the scientific design produced a clear business advantage: a bispecific that can be made in any antibody plant is a bispecific whose manufacturing costs and supply risks look like those of a conventional drug.

Buyer power was moderate, and it came in two layers. The first layer was Merus' actual customers before acquisition: its partners. Merus' revenue depended heavily on a handful of partners, as Incyte's opt-out showed.² The second layer is the eventual payer for an approved drug: insurers, health systems and government programmes. In oncology, payers have historically been willing to reimburse drugs that extend survival, and orphan and breakthrough designations support that, but price pressure is rising, especially in the United States under drug-price negotiation and in European health technology assessments.

The threat of substitutes is high. Petosemtamab competes in head and neck cancer against Keytruda-based regimens, chemotherapy, older EGFR antibodies such as cetuximab and a crowd of new entrants, including other EGFR bispecifics and antibody-drug conjugates. Its own Phase 3 comparison illustrates the dynamic: it is not trying to replace Keytruda, it is trying to be added to it. That positioning is strategically smart, because it makes Merck's blockbuster an ally rather than an enemy, but it also ties petosemtamab's commercial fate to the standard of care that Keytruda defines.

Industry rivalry is high. Big pharmaceutical companies have been increasingly willing to buy rather than build, which helped Merus' shareholders at exit, but it also means any successful mechanism attracts fast followers. Genmab's acquisition is itself a reflection of that rivalry: the buyer paid up partly to make sure a competitor did not.

Put the five forces together and they describe an industry where scientific novelty is necessary but insufficient. The structural advantages Merus enjoyed, manufacturability and screening skill, were valuable but not exclusive. Its decisive advantage, if it has one, lies in a single molecule's clinical data. That leads naturally to a more precise question about the sources of durable power.

↑ Back to Top

XIII. Hamilton's 7 Powers Framework Analysis

Hamilton Helmer's framework asks a simple question about any business: what lets it earn returns above its cost of capital over time, and why can't competitors arbitrage that advantage away? For Merus, a company that never earned a return at all, the question has to be adapted. The real question is whether Merus possessed a power that justified Genmab's $8 billion price, and whether that power will survive inside its new owner.

Scale economies were weak. Merus was a clinical-stage company with no commercial sales force and no owned manufacturing; it had no cost advantage from size. Network effects were also weak, as drug development has no meaningful equivalent of a network that grows more valuable with each user. Branding was weak too: Biclonics was known among scientists and dealmakers, but physicians prescribe molecules and data, not platforms.

Counter-positioning was the most interesting power in Merus' early life, and it has faded. When Merus committed to full-length IgG bispecifics in the 2000s, much of the industry was pursuing fragment-based designs, and incumbents with large investments in those formats had reason not to follow. That gave Merus a period of genuine distinctiveness. But by the 2020s, full-length bispecifics had become mainstream, including at Genmab. The counter-position has been absorbed by the industry, which narrows the claim to a historical advantage rather than a current one.

Switching costs are a potential future power, not a present one. If petosemtamab becomes a standard first-line regimen alongside Keytruda, oncologists who see their patients respond will be reluctant to switch, and treatment guidelines and hospital protocols will embed the combination. But that power belongs to the approved product, under Genmab, and it does not exist until approval and launch.

Cornered resource is where the bull case concentrates. Merus' MeMo mouse, its common light chain library and its patents on producing bispecifics in single cells were assets that competitors could not simply copy, and the Regeneron litigation outcome protected Merus' freedom to use them.⁶ Yet the same record shows the resource was not fully cornered: rival platforms reached the market with their own solutions, the Xencor dispute was not resolved in Merus' favour, and key mouse protections ran only to 2029.[^4]¹⁴ The more defensible cornered resource is petosemtamab itself, a specific molecule with its own composition-of-matter patents and, now, positive Phase 3 data. That is a product-level power, not a platform-level one.

Process power is the subtlest case. Merus' functional screening, the habit of building thousands of combinations and letting biology choose, is an embedded organisational capability that took two decades to build. The best evidence for it is that petosemtamab's EGFR-LGR5 pairing emerged from that process rather than from conventional design. The best evidence against it is the conversion record: despite years of partnered programmes, Merus produced one licensed-out approval and one late-stage hit, and no partnered product reached market before the sale.²¹⁴ Process power that generates one blockbuster candidate in twenty years may be real, but it is not yet proven repeatable.

Weighing those, the verdict is that Merus' durable power has been narrowed over time from a platform advantage to a product advantage. The platform was distinctive and productive, but rivals neutralised much of its uniqueness. What Genmab bought was principally petosemtamab and the people who know how to develop it, with the platform as optionality.

Three numbers will show whether that judgment holds. The first is petosemtamab's pivotal clinical record, where the latest reading is the 0.50 hazard ratio for overall survival in LiGeR-HN1, with LiGeR-HN2 still to report.³ The second is the share of the Merus business's revenue that comes from royalties and product sales rather than upfront recognition; in Merus' last full standalone year, recognised upfront payments made up roughly three-quarters of revenue, with no product royalties disclosed separately.² The third is the cost of carrying the programme, last seen at about $251 million of operating cash outflow over nine months of 2025 against about $817 million of cash, now replaced by Genmab's group-level spending and debt service.¹⁴[^27]

↑ Back to Top

Epilogue: Tonight in Utrecht

Tonight, the Merus name lives on as a subsidiary. The scientists in Utrecht now work for a Danish parent; the ticker MRUS is gone; and the drug they discovered has just cleared the hardest test in oncology. Genmab has said it will engage regulators around the world and present the full LiGeR-HN1 data at a future medical meeting.³

The next moments that will decide this story are clear. The first is the full data presentation, which will reveal median survival, absolute response rates and the safety profile behind the topline numbers. If the survival curves separate early and stay apart, petosemtamab will be positioned as a new first-line standard for PD-L1-positive head and neck cancer. If the benefit narrows with longer follow-up, or the infusion reactions look worse in a broader population, the label and the market will be smaller. The second is LiGeR-HN2, the trial in patients who have exhausted immunotherapy and chemotherapy. A positive result would add a second indication; a negative one would confine the drug to the first-line setting. The third is the regulatory filing and, if approved, the launch, which Genmab had guided could come as early as 2027.¹ The fourth sits on Genmab's balance sheet: whether it can fund petosemtamab's launch, its colorectal trials and the rest of its pipeline while servicing $5.5 billion of acquisition debt.²³[^27]

Each outcome maps onto the story's central questions. Can petosemtamab validate the value embedded in the takeout? The October result says the answer is moving towards yes, but the full data and the commercial launch still have to confirm it. Was Merus building durable revenue, or monetising its platform in uneven tranches? The record says uneven tranches, until the very end; the answer for petosemtamab will now be written in Genmab's product sales. Did the acquisition transfer the opportunity to a parent able to fund it? Genmab's resources are larger than Merus' ever were, but its debt is also larger, and the trade-off between interest and investment will be visible in its reports.

For the former Merus shareholders, the tension is sharper. They gave up the upside that the October result has begun to reveal. Whether that was wisdom or regret depends on numbers that will be published under someone else's name.

↑ Back to Top

Outro

The Merus story began with its common-light-chain mouse. It ends with its best-known molecule cutting the risk of death in half, and with the company no longer independent.

That is the strange shape of a biotech success: a long, costly bet that ended just before its defining trial. Its invention will now be measured in patients treated and revenue booked, but not on its own income statement. The common light chain made everything fit together. In the end, the company fit itself inside someone else.